KNOXVILLE, Tenn., Nov. 14 /PRNewswire-FirstCall/ -- Provectus Pharmaceuticals, Inc. , an innovative biopharmaceutical company engaged in the research and development of breakthrough technologies for metastatic melanoma, breast cancer, psoriasis and other serious diseases, announced today that significant operational and financial progress was made during the third quarter ended September 30, 2006. Financial results for the period can be found in the Form 10Q filed with the U.S. Securities and Exchange Commission (SEC), which is accessible at the SEC website at www.sec.gov.
Significant milestones reached during and subsequent to the 2006 third quarter include:
- Professor Peter Hersey, M.D., presented results at the Third Annual International Melanoma Research Congress, September 14-16, 2006, in Noordwijk, The Netherlands that outlined how the Company’s leading anti-cancer agent, PV-10, completely ablated a cluster of metastatic melanoma tumors afflicting a clinical trial participant. - The Company presented evidence at the Annual Meeting of the American Society for Photobiology that the active agent in the Company’s topical drug Xantryl(TM) may have utility in treating infections caused by highly dangerous antibiotic resistant bacteria. Xantryl(TM) is currently in clinical trials for the topical treatment of psoriasis.
Looking forward, the Company expects to reach additional clinical milestones related to its metastatic melanoma application in the upcoming periods. Significant among those will be:
- Completing treatment of Phase 1 subjects in melanoma and breast carcinoma - Publication of initial Phase 1 results, and - Initiation of the definitive Phase 2/3 metastatic melanoma study.
Provectus CEO Craig Dees, Ph.D., said, “We look forward to continuing our efforts to increase shareholder value while advancing products that should improve life for patients with critical or chronic diseases.”
About Provectus Pharmaceuticals, Inc.
Provectus Pharmaceuticals, Inc. is an innovative biopharmaceutical company actively engaged in the design, development, and marketing of pharmaceutical technologies for the treatment of breast cancer, liver cancer, and metastatic melanoma. In addition, Provectus is preparing to begin Phase 2 clinical studies for the Company’s topical agent Xantryl(TM), a treatment for psoriasis.
The Company’s offices and laboratory are located at 7327 Oak Ridge Highway, Suite A, Knoxville, TN 37931; telephone: 865 769 4011. For more information, contact the Company at info@pvct.com or visit the corporate Web site: www.pvct.com.
This release and others statements issued or made from time to time by the company or its representatives contain comments that may constitute forward- looking statements. Those include statements regarding the intent, belief or current expectations of the company and members of its management teams, as well as the assumptions on which the statements are based. Prospective investors are cautioned that such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward- looking statements.
Provectus Pharmaceuticals, Inc.
CONTACT: investors, Matt Clawson of Allen & Caron Inc, +1-949-474-4300, ormatt@allencaron.com, for Provectus Pharmaceuticals, Inc., or PeterCulpepper of Provectus Pharmaceuticals Inc, +1-865-769-4011, orculpepper@pvct.com
Web site: http://www.pvct.com//
